Trial Profile

Utilization Patterns of Pulmicort [budesonide] Hydro Fluoroaklane (HFA) Pressurized Metered-Dose Inhaler (pMDI) in Real Life Practice.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Dec 2010

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Budesonide (Primary)
Indications Asthma
Focus Therapeutic Use
Sponsors AstraZeneca

Most Recent Events

30 Nov 2010 Actual end date changed from (Mar 2009) to (Feb 2009) as reported by ClinicalTrials.gov.
06 Mar 2009 Actual patient number (60) reported by ClinicalTrials.gov.
06 Mar 2009 Actual end date reported as 1 Mar 09 by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com